Dr. Jumei Zhou 周菊梅
Chief Physician
Department of Abdominal and Lymphoma Radiation Therapy, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Three-dimensional conformal intensity-modulated radiotherapy for malignancies including nasopharyngeal, rectal, lung, esophageal, lymphoma, prostate, and breast cancers, with a focus on abdominal tumors.
Dr. Zhou holds a PhD in Clinical Oncology from Xiangya Medical College and serves as a master’s supervisor. Since graduation, Dr. Zhou has practiced clinical radiation oncology, emphasizing standardized, individualized, and comprehensive care. Dr. Zhou led one project each from the Provincial Science and Technology Department, Chinese Medical Association Exchange Fund, and hospital youth fund, participated in multiple provincial projects, published two SCI papers and over ten core journal articles, and co-authored three monographs.
Name order: in Chinese the family name comes first (Zhou Jumei). Papers usually list the name as Jumei Zhou or Zhou J.
Selected publications
18 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur Urol, 2026 (first author): Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial. PubMed 41934037
- Eur Urol, 2026 (senior author): Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer. PubMed 41741293
- Eur Urol, 2026 (senior author): Re: Disitamab Vedotin plus Toripalimab in HER2-expressing Advanced Urothelial Cancer. PubMed 41638956
- Cancer Cell Int, 2025 (senior author): UCHL3: a crucial deubiquitinase in DNA damage repair and tumor progression. PubMed 40691601
- Acad Radiol, 2024 (senior author): Radiomics Model for Predicting FOXP3 Expression Level and Survival in Clear Cell Renal Carcinoma. PubMed 37940428
- BMC Cancer, 2019 (first author): LncRNA WWC2-AS1 functions AS a novel competing endogenous RNA in the regulation of FGF2 expression by sponging miR-16 in radiation-induced intestinal fibrosis. PubMed 31262262
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion